Bimekizumab Treatment Is Associated with Improvements in Back Pain and Fatigue in Patients with Active Psoriatic Arthritis: 48-Week Results from a Phase 2b Study

被引：0
|
作者：
Deodhar, Atul [1 ]
Gossec, Laure [2 ,3 ]
Mease, Philip [4 ]
Coarse, Jason [5 ]
Edens, Heather [6 ]
De Peyrecave, Natasha [7 ]
Assudani, Deepak [7 ]
Ink, Barbara [7 ]
Ritchlin, Christopher [8 ]
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Sorbonne Univ, Paris, France
[3] Hop Univ Pitie Salpetriere, Paris, France
[4] Seattle Rheumatol Associates PLLC, Seattle, WA USA
[5] UCB Pharma, Raleigh, NC USA
[6] UCB Pharma, Smyrna, GA USA
[7] UCB Pharma, Slough, Berks, England
[8] Univ Rochester, Med Ctr, Dept Med, Rochester, NY 14642 USA
来源：
ARTHRITIS & RHEUMATOLOGY | 2020年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
0906
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Low Uveitis Rates in Patients with Axial Spondyloarthritis or Psoriatic Arthritis Treated with Bimekizumab: Long-Term Results from Phase 2b/3 Trials
    van der Horst-Bruinsma, Irene E.
    Brown, Matthew A.
    van Gaalen, Floris
    Haroon, Nigil
    Gensler, Lianne S.
    Marten, Alexander
    Manente, Myriam
    Stojan, George
    Vaux, Thomas
    White, Katy
    Deodhar, Atul
    Rudwaleit, Martin
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4741 - 4743
  • [22] Efficacy and Safety of Ixekizumab in Patients with Active Psoriatic Arthritis: 52 Week Results from a Phase 3 Study
    Mease, Philip J.
    Okada, Masato
    Kishimoto, Mitsumasa
    Shuler, Catherine L.
    Carlier, Hilde
    Lin, Chen-Yen
    Mou, Jiani
    Moriarty, Susan R.
    Lee, Chin H.
    Gladman, Dafna D.
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [23] BIMEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS: ACHIEVEMENT AND MAINTENANCE OF PSORIATIC ARTHRITIS RESPONSE CRITERIA RESPONSES THROUGH 3 YEARS IN A PHASE 2B OPEN-LABEL EXTENSION STUDY
    Tillett, William
    McInnes, Iain B.
    McGonagle, Dennis
    Jadon, Deepak R.
    Ink, Barbara
    Assudani, Deepak
    Coarse, Jason
    Eells, Jason
    Coates, Laura C.
    RHEUMATOLOGY, 2022, 61 : I20 - I20
  • [24] IZOKIBEP (ABY-035) IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS-16-WEEK RESULTS FROM A PHASE 2 STUDY
    Behrens, F.
    Taylor, P. C.
    Wetzel, D.
    Brun, N. C.
    Brandt-Juergens, J.
    Drescher, E.
    Dokoupilova, E.
    Rowinska-Osuch, A.
    Martin, N. Abdel-Kader
    de Vlam, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 170 - 171
  • [25] Bimekizumab Treatment in Biologic DMARD-Naive Patients with Active Psoriatic Arthritis: 52-Week Efficacy and Safety Results from a Phase 3, Randomized, Placebo-Controlled, Active Reference Study
    Ritchlin, Christopher
    Coates, Laura
    McInnes, Iain
    Mease, Philip J.
    Merola, Joseph
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vish
    Coarse, Jason
    Landewe, Robert
    ARTHRITIS & RHEUMATOLOGY, 2022, 74 : 4533 - 4536
  • [26] BIMEKIZUMAB TREATMENT IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY RESULTS FROM A PHASE 3, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
    Ostor, Andrew
    Ritchlin, Christopher T.
    Coates, Laura C.
    McInnes, Iain B.
    Mease, Philip J.
    Merola, Joseph F.
    Tanaka, Yoshiya
    Asahina, Akihiko
    Gossec, Laure
    Gottlieb, Alice B.
    Thaci, Diamant
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Shende, Vishvesh
    Coarse, Jason
    Landewe, Robert
    INTERNAL MEDICINE JOURNAL, 2023, 53 : 26 - 26
  • [27] Week 48 results from the phase 2b ENLIVEN extension study investigating pegozafermin for the treatment of metabolic dysfunction-associated steatohepatitis with fibrosis
    Loomba, Rohit
    Abdelmalek, Manal F.
    Kowdley, Kris V.
    Alkhouri, Naim
    Harrison, Stephen A.
    Schattenberg, Joern M.
    Gottwald, Mildred D.
    Feng, Shibao
    Agollah, Germaine D.
    Hartsfield, Cynthia L.
    Mansbach, Hank
    Margalit, Maya
    Sanyal, Arun J.
    JOURNAL OF HEPATOLOGY, 2024, 80 : S72 - S72
  • [28] Bimekizumab treatment response is maintained up to 3 years in patients with psoriatic arthritis: Responder analyses from BE ACTIVE, a phase 2b dose-ranging study, and its open-label extension
    Merola, Joseph F.
    Asahina, Akihiko
    Ritchlin, Christopher T.
    Ink, Barbara
    Assudani, Deepak
    Bajracharya, Rajan
    Coarse, Jason
    Eells, Jason
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (03) : AB146 - AB146
  • [29] The effect of guselkumab on psoriasis in patients with active psoriatic arthritis: results from a phase 2 study
    Gottlieb, A. B.
    Wolf-Henning, B.
    Helliwell, P.
    Deodhar, A.
    Ozturk, B.
    Xu, X. L.
    Xu, S.
    Wang, Y.
    Zhuang, Y.
    Hsia, E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 : 36 - 37
  • [30] The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis
    Gladman, Dafna D.
    Boehncke, Wolf-Henning
    Gottlieb, Alice B.
    Helliwell, Philip
    Nash, Peter
    Xu, Xie L.
    Xu, Stephen
    Wang, Yuhua
    Hsia, Elizabeth C.
    Karyekar, Chetan S.
    Deodhar, Atul A.
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345